Trinity Biotech (TRIB) Cash from Restructuring (2013 - 2024)

Trinity Biotech (TRIB) posted Cash from Restructuring of $339.0 for Q3 2024, down 82.52% sequentially from $1939.0 in Q2 2024.

Trinity Biotech (TRIB) Cash from Restructuring (2013 - 2024) Analysis & Trends

Trinity Biotech has reported Cash from Restructuring for 2 years, with the latest figure at $339.0 in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	200.51 Bn	194.91 Bn	7.27 Bn
2	Stryker	129.96 Bn	126.48 Bn	4.50 Bn
3	Medtronic	120.18 Bn	110.96 Bn	6.41 Bn
4	Boston Scientific	74.28 Bn	73.74 Bn	3.85 Bn
5	Edwards Lifesciences	52.75 Bn	48.50 Bn	1.35 Bn
6	Dexcom	34.67 Bn	32.73 Bn	830.00 Mn
7	GE HealthCare Technologies	34.23 Bn	32.12 Bn	2.18 Bn
8	Koninklijke Philips	26.46 Bn	23.14 Bn	4.55 Bn
9	Steris	23.30 Bn	22.82 Bn	684.20 Mn
10	Trinity Biotech	6.82 Mn	1.68 Mn	-

Download Data